清心定志汤联合维思通治疗首发精神分裂症患者认知功能及对血清miR-132、miR-137、miR-206水平的影响

Qingxin Dingzhi Tang Combined with Risperidone Has Effect on Cognitive Function and Levels of miR-132,miR-137 and miR-206 in Serum of Patients with First-episode Schizophrenia

目的:观察清心定志汤联合维思通对首发精神分裂症患者认知功能及血清微小核糖核酸-132 (miR-132)、微小核糖核酸-137 (miR-137)、微小核糖核酸-206 (miR-206)水平的影响。方法:将120例首发精神分裂症患者随机分为2组,每组60例;对照组采用维思通治疗,研究组采用清心定志汤联合维思通治疗,2组均治疗8周;比较2组患者临床疗效、认知功能及血清miR-132、miR-137、miR-206水平的变化,同时记录2组患者的不良反应发生情况。结果:总有效率研究组为96.67%,对照组为81.67%,2组比较,差异有统计学意义(P <0.05)。治疗后,2组韦氏记忆量表评分(WMS)、简明精神状态量表(MMSE)评分均较治疗前明显升高(P <0.05),且研究组WMS、MMSE评分均高于对照组(P <0.05)。治疗后,2组miR-132、miR-137、miR-206水平均较治疗前明显降低(P <0.05),且研究组上述各指标水平均低于对照组(P <0.05)。不良反应发生率研究组为15.00%。对照组为40.00%,2组比较,差异有统计学意义(P <0.05)。结论:清心定志汤联合维思通治疗首发精神分裂症疗效优于单用维思通,可明显改善患者的认知功能和降低患者血清miR-132、miR-137、miR-206的表达水平,且安全性高。

Objective: To observe the effect of Qingxin Dingzhi tang combined with risperidone on cognitive function and levels of microRNA-132(miR-132), microRNA-137(miR-137) and microRNA-206(miR-206) in serum of patients with first-episode schizophrenia. Methods: Divided 120 cases of patients with first-episode schizophrenia into two groups randomly, 60 cases in each group. The control group received risperidone for treatment,while the study group received Qingxin Dingzhi tang combined with risperidone. The treatment lasted for eight weeks in the two groups. Compared the clinical effect, cognitive function and the change in levels of miR-132, miR-137 and miR-206 in serum, and recorded the adverse reactions in the two groups. Results: The total effective rate was 96.67% in the study group and was 81.67% in the control group,the difference being significant(P < 0.05). After treatment, scores of WMS and MMSE in the two groups were obviously increased when compared with those before treatment(P < 0.05), and the scores of WMS and MMSE in the study group were higher than those in the control group(P< 0.05). After treatment, levels of miR-132, miR-137 and miR-206 in serum in the two groups were obviously decreased when compared with those before treatment(P < 0.05),and the levels of the above indexes were lower than those in the control group(P < 0.05). The incidence of adverse reactions was 15.00% in the study group and was 40.00% in the control group,the difference being significant(P < 0.05). Conclusion: The therapy of Qingxin Dingzhi tang combined with risperidone has better effect in treating first-episode schizophrenia than that of simple treatment of risperidone, which can significantly improve the cognitive function and decrease the impression of levels of miR-132,miR-137 and miR-206 in serum with high safety.